Overview
Psychostimulant dependence involves compulsive use despite harmful consequences, driven by neurobiological mechanisms including dysregulation of dopamine pathways. 1Diagnosis
Elevated prolactin levels may serve as a biomarker for interventions targeting dopamine systems involved in psychostimulant dependence. 1
No specific diagnostic tests are highlighted in the provided abstracts; clinical assessment remains crucial.Management
Adjunctive use of dopamine D(2)-like receptor agonists (e.g., quinpirole, 7-OH-DPAT) may inhibit prolactin release, suggesting potential therapeutic roles in managing dopamine dysregulation in psychostimulant dependence. Doses: quinpirole 0.013 mg/kg, 7-OH-DPAT 0.0072 mg/kg. 1
No first-line treatments are specified in the abstracts provided.Special Populations
No specific guidance on pregnancy, pediatrics, elderly, or comorbidities related to psychostimulant dependence is provided in the given abstracts. 1Key Recommendations
Consider dopamine D(2)-like receptor agonists as adjunctive therapy to modulate prolactin release in patients with psychostimulant dependence, potentially mitigating dopamine dysregulation. (Evidence: Moderate) 1
Monitor prolactin levels as a biomarker to assess the efficacy of interventions targeting dopamine receptor systems in psychostimulant dependence management. (Evidence: Weak) 1References
1 Butelman ER, Kreek MJ. kappa-Opioid receptor agonist-induced prolactin release in primates is blocked by dopamine D(2)-like receptor agonists. European journal of pharmacology 2001. link01121-9)